Diem, Stefan; Fässler, Mirjam; Bomze, David; Ali, Omar Hasan; Berner, Fiamma; Niederer, Rebekka; Hillmann, Dorothea; Mangana, Joanna; Levesque, Mitchell P; Dummer, Reinhard; Risch, Lorenz; Recher, Mike; Risch, Martin; Flatz, Lukas (2019). Immunoglobulin G and Subclasses as Potential Biomarkers in Metastatic Melanoma Patients Starting Checkpoint Inhibitor Treatment. Journal of immunotherapy, 42(3), pp. 89-93. Wolters Kluwer Health 10.1097/CJI.0000000000000255
|
Text
Immunoglobulin_G_and_Subclasses_as_Potential.3.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (233kB) | Preview |
Checkpoint inhibitors have improved survival of metastatic melanoma. However, reliable biomarkers to predict response are still needed. Immunoglobulin G (IgG) antibody subclasses reflect immunocompetence in individuals and are known to be involved in essential functions in our immune system. This prospective study evaluated the association between serum IgG with its subclasses IgG1, IgG2, IgG3, and IgG4 and antitumor response according to RECIST 1.1. Serum samples from 49 patients were prospectively collected before the start of treatment with a checkpoint inhibitor. We observed a statistically significant association of baseline IgG2 with response to therapy (P=0.011). After defining optimal cutpoints, we found significant associations between total IgG (>9.66 g/L, P=0.038), IgG1 (>6.22 g/L, P=0.025), IgG2 (>2.42 g/L, P=0.019), and IgG3 (>0.21 g/L, P=0.034) with progression-free survival. Prolonged overall survival was associated with elevated IgG2 (>2.42 g/L, P=0.043). Together, these findings define total IgG and subclasses as predictors of clinical successful checkpoint inhibition in metastatic melanoma patients.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Institute of Clinical Chemistry |
UniBE Contributor: |
Risch, Lorenz |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
1537-4513 |
Publisher: |
Wolters Kluwer Health |
Language: |
English |
Submitter: |
Karin Balmer |
Date Deposited: |
23 Nov 2022 07:17 |
Last Modified: |
05 Dec 2022 16:28 |
Publisher DOI: |
10.1097/CJI.0000000000000255 |
PubMed ID: |
30768543 |
BORIS DOI: |
10.48350/174993 |
URI: |
https://boris.unibe.ch/id/eprint/174993 |
Actions (login required)
 |
Edit item |